Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin

• Main Authors: Teh, L. K., Langmia, I. M., M. H., Fazleen Haslinda, Ngow, Harris Abdullah, Roziah, M. J., Harun, R., Zakaria, Z. A., Salleh, M. Z.
• Format: Article
• Language: English
• Published: Blackwell Publishing 2011
• Subjects: QP Physiology; RC Internal medicine; RM Therapeutics. Pharmacology
• Online Access: http://irep.iium.edu.my/5105/2/Cyp2c9_and_VKROC.pdf; http://irep.iium.edu.my/5105/

What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles is recommended by the FDA for dosing of warfarin. However, dose prediction models derived from data obtained in one population may not be applicable to a...